Kyntra Bio is a biopharmaceutical company focused on developing novel therapies in oncology and rare disease. Its pipeline includes FG-3246 (FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 currently in Phase 2 development for metastatic castration-resistant prostate cancer, along with FG-3180, an associated CD46-targeted PET imaging agent being developed as a companion diagnostic biomarker. The company also develops roxadustat, an oral HIF-PH inhibitor that promotes red blood cell production and is approved in Europe, Japan, China, and other countries for treating anemia in chronic kidney disease patients. Kyntra Bio holds sole rights to roxadustat in the United States, Canada, Mexico, and other markets not held by AstraZeneca or licensed to Astellas, and is evaluating a Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndromes in the U.S. The company collaborates with Astellas on roxadustat commercialization in territories including Japan, Europe, Turkey, Russia, CIS countries, the Middle East, and South Africa. FG-3246 is exclusively in-licensed from Fortis Therapeutics. Updated
Monday's top analyst upgrades and downgrades included Apple, Automatic Data Processing, Bowlero, Dell Technologies, Dollar General, Macy’s, MongoDB, Paychex, SentinelOne, Trade Desk, Valvoline, Warner Music and Xcel Energy.
Wednesday's top analyst upgrades and downgrades included Broadcom, Clean Energy Fuels, Dish Network, First Republic Bank, Gaming and Leisure Properties, Occidental Petroleum, Revolution Medicines, Veeva Systems and Workday.
Friday's top analyst upgrades and downgrades included Datadog, DexCom, Exelixis, Lam Research, Las Vegas Sands, Lyft, Match, Nasdaq, Next Era Energy, Norfolk Southern, Pfizer, Walmart and Wolfspeed.
Friday's top analyst upgrades and downgrades included Ally Financial, American Express, AppLovin, AstraZeneca, Coinbase Global, Cognizant Technology Solutions, Comcast, CME, CrowdStrike, Delta Air Lines, Danaher, Dropbox, Marathon Oil, Microsoft and Target.
Wednesday's top analyst upgrades and downgrades included Accenture, FedEx, McAfee, PubMatic, ServiceNow, Sofi Technologies, Trade Desk and Vale.
Friday's top analyst upgrades and downgrades included Duke Energy, Macy's, Mosaic, Nvidia, SAP, ServiceNow, Shopify and Workday.
Friday's top analyst upgrades and downgrades included Alibaba, Chewy, Danaher, Energy Transfer, LyondellBasell, LiveNation, Salesforce, Seagate, Splunk and Textron.
Kyntra Bio is a biopharmaceutical company focused on developing novel therapies in oncology and rare disease.
